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Ovarian cancer is the fifth most common cancer in UK women, and the leading cause of 
gynaecological cancer death. Five-year survival rates, of around 40%, have shown little 
improvement despite recent advances in cancer treatment. Mutations in the cancer 
susceptibility genes BRCA1 and BRCA2 confer lifetime risks of breast and ovarian cancer of 
up to 80% and 40% respectively.1 The traditional approach of using cancer family history to 
select patients for genetic testing is being challenged; up to 44% of BRCA mutation carriers 
do not have a significant family history.2 Recent research has shown that offering BRCA 
testing to all women with high grade non-mucinous ovarian cancer is an effective approach 
to identifying more BRCA carriers.3, 4 Furthermore, there is an opportunity to prevent ovarian 
cancer if women at increased risk can be identified before developing the disease.  
 
Progress in technology means it is faster and cheaper to conduct large-scale genetic testing, 
making the introduction of population-based genetic testing for cancer risk prediction viable. 
Although genetic information has not yet been incorporated into cancer screening 
programmes, researchers are exploring population-based genetic risk estimation for 
women’s cancers.5, 6 This has the potential to reduce ovarian cancer morbidity and mortality 
by stratifying screening and preventive interventions on the basis of prior risk. Here we 
consider recent social and scientific advances that suggest population-based genetic testing 
could be implemented, and the challenges that remain.  
 
Ongoing research in ovarian cancer has led to increased knowledge about genetics, risk 
factors, pathogenesis and early symptoms. Ovarian cancer is not a single disease; distinct 
histological types have different epidemiological and gene expression profiles which may 
influence treatment and prognosis. High grade serous (HGS) ovarian cancer is the most 
common subtype. Recent evidence indicates HGS ovarian cancers may arise from the 
fallopian tube and not the epithelial surface, with the identification of serous tubal 
intraepithelial carcinoma (STIC) lesions in up to 40% of advanced or symptomatic cases.7 
Endometrioid and clear cell carcinomas appear to develop from ectopic endometrium, whilst 
invasive mucinous cancers are metastases to the ovary from other solid tumours.8  
 
 
There has been a shift in our understanding of ovarian cancer genetics. To date there are at 
least 16 genes and more than 10 single nucleotide polymorphisms (SNPs) associated with 
increased ovarian cancer risk. The best understood are the high penetrance BRCA1, 
BRCA2 and Lynch syndrome genes which confer lifetime risks from 7-40% for ovarian 
cancer.1, 9 Increasingly, moderate penetrance genes such as BRIP1, RAD51C and RAD51D 
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with lifetime risks of 6-13%10 are being used in multi-gene panels for clinical genetic testing. 
The residual genetic risk may be explained by common low penetrance susceptibility genes. 
Population-based genome wide association studies (GWAS) have identified SNPs with 
relative risks of around 1%.11 SNPs are not currently used in clinical testing, although they 
may also play a role in moderating risk in BRCA carriers and are increasingly incorporated in 
risk models for ovarian cancer.12  
 [TABLE 1 here] 
 
Although the prognosis for women with advanced ovarian cancer is poor, disease confined 
to the ovary has a five-year survival rate of more than 90%. Early detection has the potential 
to significantly improve ovarian cancer outcomes. The United Kingdom Collaborative Trial of 
Ovarian Cancer Screening (UKCTOCS), showed that more early stage cancers were 
identified by multimodal screening; 38% (107/283) of invasive epithelial ovarian and tubal 
cancers were identified at stage I or II in the multimodal arm, compared to 23% (58/249) with 
ultrasound or 24% (136/559) no screening.13 By using a risk algorithm with serial CA-125 
biomarker measurement rather than the typical fixed threshold, the number of screen-
detected ovarian cancers was doubled.14 When prevalent cases and primary peritoneal 
cancers were excluded from the analysis, mortality was significantly reduced by 20%. There 
are however, wide confidence limits around this estimate, and an additional two to three 
years of follow-up will be required to determine the actual reduction of mortality. A large 
prospective study of screening in women at high risk, the UK Familial Ovarian Cancer 
Screening Study (UKFOCSS), used 4-monthly CA-125 biomarker and risk algorithm 
interpretation. Early data from the Phase II trial indicated encouraging sensitivity and 
specificity, although final results are yet to be reported.15 CA-125 has typically been ‘the gold 
standard’ biomarker in ovarian cancer; research is ongoing to identify biomarkers with 
superior sensitivity and specificity. Human epididymis protein 4 (HE4) has comparable 
performance to CA-125 and when used in combination have demonstrated improved 
diagnostic performance; other candidate biomarkers also show promise.16   
 
Counselling frameworks and risk reducing interventions are well defined for BRCA and 
Lynch syndrome carriers. Bilateral salpingo-oophorectomy (BSO) remains the most effective 
measure to reduce the risk of ovarian cancer, but is currently only recommended for women 
with a lifetime risk of >10%. However BSO may be considered for women at lower risks 
associated with moderate penetrance genes, given the current lack of mortality benefit from 
ovarian cancer screening.10 Furthermore BSO has been shown to be cost-effective at ≥4% 
lifetime risk of ovarian cancer.17 Developments in our understanding of the pathogenesis of 
ovarian cancer may provide other options for prevention. Bilateral salpingectomy followed by 
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delayed oophorectomy is being considered as an alternative to BSO. This approach could 
avoid premature menopause, but more research is needed to evaluate the impact of 
salpingectomy on reducing ovarian cancer risk.  
 
Genetic tests are already used in a number of population-based screening programmes. 
Community carrier testing programmes for Tay Sachs disease within the Ashkenazi Jewish 
population have been in place since the 1970s. Within the UK, the largest population 
screening program for genetic conditions is the NHS Newborn Blood Spot Screening 
Programme which tests for diseases including sickle cell disease, cystic fibrosis and 
metabolic disorders. 
 
Population-based genetic testing for breast and ovarian cancer susceptibility has been 
studied in the unaffected UK Ashkenazi Jewish population, demonstrating the feasibility of 
this approach. Data from the Genetic Cancer Prediction through Population Screening 
(GCaPPS) study showed that 56% more BRCA carriers were identified by population 
screening compared to selection based on family history, with no adverse short-term 
psychological outcomes. 18 This provides a paradigm for broader population genetic 
screening.  
 
Although BRCA gene mutations are associated with both hereditary breast and ovarian 
cancer (HBOC), the link with ovarian cancer is less well recognised. Reflecting its moniker of 
an ‘invisible disease’, ovarian cancer has had a low profile in terms of public awareness. 
With a growing number of ovarian cancer charities, a Cancer Research UK ‘Be Clear on 
Cancer’ campaign and an ovarian cancer awareness month, this is beginning to change. 
The most recent event to bring breast and ovarian cancer genetics into the spotlight is the 
‘Angelina effect’. Actor and filmmaker Angelina Jolie disclosed her BRCA1 mutation status 
and decision to have risk-reducing bilateral mastectomy in 2013 and BSO in 2015. From the 
public interest that followed, referral rates to familial cancer clinics increased significantly.19 
Her story raised public awareness of breast and ovarian cancer risk and the management 
options available, as well as the role of genetic testing in preventing cancer.  
 
With increasing interest in incorporating genetic testing into routine clinical care, researchers 
are studying the public’s response to learning whether they have a genetic susceptibility to 
certain diseases, including cancer. Overall, attitudes to genetic testing for cancer risk have 
been positive and interest in testing is high.20 When examining this in the context of ovarian 
cancer and subsequent risk-stratified screening, women felt genetic testing would be 
‘indisputably beneficial’ and knowledge of this risk could be ‘empowering’.6 Similarly, from a 
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survey of 930 women, more than 80% would have genetic testing to learn their risk of 
ovarian cancer and more than 90% would participate in risk-stratified screening.21 These 
findings are encouraging and convey enthusiasm for genetic risk stratification from the 
general public. However, most of our experience of ‘real’ genetic testing for cancer 
susceptibility is in high-risk groups, such as individuals with a strong family history of cancer. 
In families with a mutation predisposing to cancer, interest in genetic testing is high although 
actual uptake varies from 25% to 96%.22 Given the gap between intention and actual uptake 
of genetic testing in high-risk patient groups, caution is needed when considering how 
women from the general population might respond to genetic risk stratification for ovarian 
cancer. Research into public attitudes towards genetic testing for cancer susceptibility has 
been promising, but is limited because it has only studied hypothetical intent to take part in 
such a programme.  
 
Despite the encouraging progress in ovarian cancer genetics and aetiology, screening and 
risk management, as well as public attitudes and awareness, there remain challenges to the 
introduction of a population-based genetic testing programme for this disease. Existing 
population-based BRCA genetic testing programs in the UK and the United States have 
focused on Ashkenazi Jewish groups, where carrier frequencies are high and known founder 
mutations facilitate testing. Similarly, cost-benefit analyses of population-based BRCA 
genetic testing have only been undertaken for Ashkenazi Jewish groups. Advances in 
genetic testing mean that it is increasingly affordable to simultaneously test multiple genes; 
further research is needed to look at the cost effectiveness of such testing in terms of cancer 
prevention in the general population.    
 
Women participating in a screening programme need to be fully informed of its risks and 
benefits. Furthermore, genetic testing can have implications for their relatives. To date, face-
to-face genetic counselling has been an integral part of clinical genetic testing. Providing 
genetic testing to a large population requires new ways of information provision and 
counselling. Novel approaches, such as using online tools and decision aids, will be 
essential.   
 
Genetic testing is relatively non-invasive, typically involving collection of a blood or saliva 
sample. However, there may be psychological costs, such as a short term increase in 
distress after receiving adverse test results.23 Additionally, receiving a normal genetic test 
result could provide false reassurance, as women deemed to be at ‘low risk’ could still 
develop ovarian cancer due to other genetic and environmental factors. Variants of unknown 
significance (VUS) are genetic alterations where the pathogenicity is uncertain. These 
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uninformative results can be confusing to both patients and clinicians and careful 
consideration should be given as to how, or indeed whether, they should be reported. 
Management strategies for women at increased genetic risk of ovarian cancer will be key, 
with appropriate interventions and follow-up care required.  
  
In conclusion, incorporating genetic testing into cancer screening programmes allows early 
detection and risk-reducing measures to be targeted to those at greatest risk. Importantly, 
this risk-stratification approach may also minimise screening and medical interventions in 
low risk individuals. Current cancer screening programmes in the UK are stratified by age 
and gender only. Given the recent debate about overdiagnosis in breast cancer screening,24 
stratifying risk using factors such as breast density or genetic predisposition may be 
beneficial. 
 
Advanced ovarian cancer is a disease with a poor prognosis. If women at increased genetic 
risk can be identified, an effective strategy for disease prevention exists through risk-
reducing BSO. The risk association with BRCA1/2 mutations and other ovarian cancer 
susceptibility genes is increasingly well understood. Ovarian cancer screening by CA-125 
serial biomarker measurements shows some potential for early detection. Ovarian cancer 
biology, including genetics, remains an area of intense research. There is greater awareness 
of ovarian cancer, increasing public interest in genetic testing, and novel risk management 
options. Innovative approaches, such as looking at epigenetic biomarkers to detect early 
stage disease, are showing promise.25  Public health policy is beginning to embrace the 
concept of genetic risk prediction for disease stratification. A recent public enquiry by the UK 
House of Commons Science and Technology Committee into national health screening 
‘…welcomes the current, ongoing research that aims to improve the targeting of screening 
programmes towards those in higher risk groups’.26 
 
Despite the challenges associated with implementing such a programme, with further 
research these may be addressed. The potential for reducing the burden of ovarian cancer 
through population-based genetic testing warrants further investigation.    
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Table 1. Genetic basis of ovarian cancer 
Genetic susceptibility associated with ovarian cancer 
High penetrance Associated with HBOC and Lynch 
syndrome 
BRCA1, BRCA2, MSH2, MSH6, 
MLH1, PMS2 and EPCAM 
Moderate penetrance Susceptibility genes BRIP1, RAD51C and RAD51D 
Low penetrance Common variant susceptibility loci 9p22, 2q31, 8q24, 3q25,19p13, 
17q21, 1p36, 4q26, 9q34.2, 
17q11.2 
  
